Monopar Therapeutics Inc. (MNPR) Earnings History
Net Loss11 years of earnings data (2015–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Monopar Therapeutics Inc. (MNPR) Earnings Overview
As of June 22, 2026, Monopar Therapeutics Inc. (MNPR) reported trailing twelve-month net income of -$15M, reflecting -36.0% year-over-year growth. The company earned $-1.76 per diluted share over the past four quarters.
Looking at the long-term picture, MNPR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$687,000 in fiscal 2015.
Monopar Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CLDX (-$284M net income, -17253.3% margin), IMVT (-$506M net income), TPVG (-$12M net income, 50.6% margin), MNPR has comparable earnings metrics. Compare MNPR vs CLDX →
MNPR Earnings vs Peers
Earnings metrics vs comparable public companies
MNPR Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$14M | +12.0% | -$17M | $-1.85 | - | - |
| 2024 | -$16M | -85.5% | -$16M | $-1.36 | - | - |
| 2023 | -$8M | +20.1% | -$9M | $-0.58 | - | - |
| 2022 | -$11M | -15.5% | -$11M | $-0.83 | - | - |
| 2021 | -$9M | -44.4% | -$9M | $-0.73 | - | - |
| 2020 | -$6M | -49.2% | -$7M | $-0.58 | - | - |
| 2019 | -$4M | -30.9% | -$4M | $-0.40 | - | - |
| 2018 | -$3M | +80.5% | -$3M | $-0.31 | - | - |
| 2017 | -$17M | -1296.3% | -$17M | $-1.59 | - | - |
| 2016 | -$1M | -72.6% | -$1M | $-0.12 | - | - |
| 2015 | $-687,000 | - | $-689,000 | $-0.08 | - | - |
Download Data
Export MNPR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MNPR — Frequently Asked Questions
Quick answers to the most common questions about buying MNPR stock.
What is MNPR earnings per share (EPS)?
MNPR trailing twelve-month (TTM) diluted EPS is $-1.76, reflecting -36.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is Monopar Therapeutics Inc.'s net income?
Monopar Therapeutics Inc. (MNPR) trailing twelve-month net income is $-15M as of 2025. Earnings declined -36.0% year-over-year.
Is MNPR profitable?
MNPR is not currently profitable on a TTM basis, reporting a net loss of $-15M. Net margin is N/A. Investors should monitor for a return to profitability.
What is MNPR's earnings growth rate?
MNPR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are MNPR's profit margins?
Monopar Therapeutics Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -14.2%.
Is MNPR growing earnings?
MNPR earnings are declining — EPS fell -36.0% year-over-year. TTM net income dropped to $-15M. This contrasts with the 5-year CAGR of N/A.
What was MNPR's best earnings year?
Monopar Therapeutics Inc.'s highest annual net income on record is $-687000.00, achieved in fiscal year 2015. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were MNPR's earnings last quarter?
MNPR's most recent reported quarter was Q1 2026. Net income was $-4M with diluted EPS of $-0.46. For a full breakdown of all quarters, see the quarterly earnings table on this page.